A Randomized, Placebo-controlled, Observer-blinded Study, to Evaluate Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of RO7239958 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
Latest Information Update: 05 Aug 2020
At a glance
- Drugs RO 7239958 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 30 Jul 2020 Status changed from active, no longer recruiting to discontinued.
- 19 May 2020 Status changed from recruiting to active, no longer recruiting.
- 07 Apr 2020 Planned number of patients changed from 82 to 75.